Differences between amyloid toxicity in alpha and beta cells in human and mouse islets and the role of caspase-3
- First Online:
- Cite this article as:
- Law, E., Lu, S., Kieffer, T.J. et al. Diabetologia (2010) 53: 1415. doi:10.1007/s00125-010-1717-9
- 759 Downloads
Type 2 diabetes is characterised by decreased beta cell mass and islet amyloid formation. Islet amyloid formed by aggregation of human islet amyloid polypeptide (hIAPP) is associated with beta cell apoptosis. We used human and transgenic mouse islets in culture to examine whether deletion of caspase-3 protects islets from apoptosis induced by endogenously produced and exogenously applied hIAPP and compared hIAPP toxicity in islet alpha and beta cells.
Human and wild-type or caspase-3 knockout mouse islet cells were treated with hIAPP. Rat insulinoma INS-1 cells were similarly cultured with hIAPP and the amyloid inhibitor Congo Red or caspase-3 inhibitor. Human and hIAPP-expressing caspase-3 knockout mouse islets were cultured to form amyloid fibrils and assessed for beta and alpha cell apoptosis, beta cell function and caspase-3 activation.
hIAPP-treated INS-1 cells had increased caspase-3 activation and apoptosis, both of which were reduced by inhibitors of amyloid or caspase-3. Similarly, hIAPP-treated human and mouse islet beta cells had elevated active caspase-3- and TUNEL-positive cells, whereas mouse islet cells lacking caspase-3 had markedly lower beta cell but comparable alpha cell apoptosis. During culture, human islets that formed amyloid had higher active caspase-3- and TUNEL-positive beta cells than those without detectable amyloid. Finally, cultured hIAPP-expressing mouse islets lacking caspase-3 had markedly lower beta cell apoptosis than those expressing caspase-3, associated with an increase in islet beta cell/alpha cell ratio, insulin content and glucose response.
Prevention of caspase-3 activation protects islet beta cells from apoptosis induced by fibrillogenesis of endogenously secreted and exogenously applied hIAPP. Islet beta cells are more susceptible to hIAPP toxicity than alpha cells cultured under the same conditions.
KeywordsAlpha cell apoptosisAmylinAmyloidBeta cell apoptosisCaspase-3Islet amyloid polypeptideType 2 diabetes
Human islet amyloid polypeptide
Rat islet amyloid polypeptide
Type 2 diabetes is characterised by progressive beta cell dysfunction, decreased beta cell mass, and islet amyloid deposition [1–5]. Islet amyloid formation caused by aggregation of human islet amyloid polypeptide (hIAPP, amylin) [6, 7] is associated with beta cell apoptosis and contributes to progressive beta cell death in type 2 diabetes [3–5]. Interestingly, islet amyloid also forms in human islets during culture  and following transplantation into mouse models of type 1 diabetes . Importantly, widespread amyloid deposition was recently reported in human islets that had been transplanted into a type 1 diabetic patient .
hIAPP, the major component of islet amyloid, is a beta cell peptide that is co-localised and co-secreted with insulin in response to beta cell secretagogues [11–13]. It is not clear why normally soluble hIAPP molecules form toxic aggregates in type 2 diabetes. It has been proposed that the presence of an amyloidogenic sequence in the hIAPP molecule [14, 15], elevated hIAPP production/secretion from beta cells associated with increased insulin demand [13, 15], and defects in trafficking/processing of proIAPP because of beta cell dysfunction [16–18] all contribute to hIAPP aggregation in type 2 diabetes.
Previous in vitro studies have suggested different mechanisms for hIAPP toxicity, including formation of non-selective ion channel-like structures [19–23], activation of the caspase pathways [24, 25], and interaction of hIAPP fibrils with components of beta cell membranes, such as heparan sulphate proteoglycan [26, 27] or touch receptors . It is, however, not clear which of these mechanism(s) contribute to hIAPP-induced beta cell death in primary islets, in which the level of endogenously produced hIAPP (pmol/l) is several fold lower [4, 29] than that used in vitro (μmol/l). Recent studies using transgenic rodents have demonstrated that endoplasmic reticulum (ER) stress caused by formation of intracellular hIAPP fibrils [30, 31] and oxidative stress  also contribute to cytotoxic effects of hIAPP. It therefore appears that, at least in vitro, hIAPP-induced beta cell apoptosis involves different mechanisms, although these mechanisms may share the same apoptotic signalling pathways. Also, the apoptotic effects of hIAPP on islet alpha cells and their potential differences from beta cells have yet to be studied.
Caspase-3 is the key downstream enzyme in the three major identified apoptotic pathways including: (1) mitochondrial (or intrinsic) initiated through cell stress, such as mitochondrial dysfunction, oxygen free radicals, metabolic toxins and anoxia; (2) cell death receptor (or extrinsic) initiated by activation of cell membrane death receptors such as Fas; and (3) ER stress initiated by misfolding/accumulation of proteins within the ER and Golgi apparatus [4, 33–35]. In this study, we used two ex vivo models of islet amyloid formation, cultured human islets and mouse islets expressing hIAPP but lacking caspase-3, as well as transformed and primary islet cells, to examine whether deletion of caspase-3 can protect islets from hIAPP aggregates derived from endogenously secreted and exogenously applied hIAPP. We also tested whether different susceptibility of islet beta and alpha cells to amyloid toxicity may contribute to better survival of islet alpha cells than beta cells, leading to selective beta cell death in conditions associated with islet amyloid formation such as type 2 diabetes, islet culture and transplantation.
Thioflavin S, dithizone, BSA, Congo Red, HEPES buffer, 2-mercaptoethanol, sodium bicarbonate, poly-l-lysine, Triton X-100, dimethyl sulfoxide (DMSO), 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), Avertin and collagenase (type XI) were obtained from Sigma-Aldrich (Oakville, ON, Canada). RPMI-1640, FBS, penicillin, streptomycin, gentamicin, cell dissociation buffer enzyme-free Hanks’-based, Ham’s-F10, trypsin-EDTA, and Glutamax were from Invitrogen Canada (Burlington, ON, Canada). Synthetic hIAPP and rat IAPP (rIAPP) (1-37), caspase-3 inhibitor (z-DEVD-FMK) and pan-caspase inhibitor (z-VD-FMK) were from Bachem (Torrance, CA, USA), and Alamar Blue dye from Biosource International (Camarilli, CA, USA). CMRL final wash/culture medium was from Mediatech (Hemdon, VA, USA).
Freshly isolated human islets from cadaveric pancreatic donors were provided by the Ike Barber Human Islet Transplantation Centre (Vancouver, BC, Canada) in accordance with approved procedures and guidelines of the Clinical Research Ethics Board of the University of British Columbia. Islets were hand-picked and purity was assessed by dithizone staining. Isolated islets (purity ∼90%) were cultured in non-adherent 24 well culture plates (50 islets per well) in CMRL (5.5 mmol/l glucose) supplemented with 10% (vol./vol.) FBS, 50 U/ml penicillin, 50 μg/ml streptomycin and 50 μg/ml gentamicin in humidified 5% CO2/95% air at 37°C overnight to allow recovery and then cultured in 11.1 mmol/l glucose for 7 days.
To generate mice producing hIAPP but lacking caspase-3, hemizygous transgenic mice producing hIAPP in their pancreatic beta cells (hIAPP+/−) were cross-bred with caspase-3 knockout mice (Casp3−/−). The offspring (hIAPP+/−/Casp3+/−) mice were bred together and the first generation of these breeders was used for the experiments. hIAPP-expressing mice were maintained by breeding hIAPP-expressing C57BL/6 mice from the VA Puget Sound Health Care System (kindly provided by S. Kahn, University of Washington, WA, USA) with DBA/2J mice (Jackson Laboratory, Bar Harbor, ME, USA). hIAPP-expressing mice form islet amyloid and develop diabetes in the presence of a predisposing factor such as high-fat diet . Casp3−/− mice were maintained by breeding Casp3+/− mice from the Ontario Cancer Institute . Casp3−/− mice have reduced apoptosis, which is tissue- and stimulus-specific [37, 38] and have normal islet structure without any marked abnormality in islet baseline viability . All animals were fed a diet containing 9% (wt/wt) fat (Purina #5021, LabDiet, Richmond, IN, USA). Animals were cared for in accordance with guidelines of the Canadian Council on Animal Care and the University of British Columbia.
Islet isolation and culture
Animals were anaesthetised with Avertin (0.02 ml/g body weight, i.p.) and killed by cervical dislocation. The abdominal cavity was opened and 2.5 ml ice-cold collagenase (type XI, Sigma) in Hanks’ solution without CaCl2 (final concentration: 525 U/ml) was injected via the common bile duct. Harvested pancreases were incubated with collagenase/Hanks’ solution (525 U/ml) at 37°C for 12.5–14 min in a shaker water-bath (120 rpm). Digestion was stopped by addition of ice-cold Hanks’ containing 1 mmol/l CaCl2. Digested pancreatic tissues were rinsed with the same solution, resuspended in Ham’s-F10 supplemented with 0.5% (wt/vol.) BSA, penicillin (50 U/ml) and streptomycin (50 μg/ml), and filtered through a 70 μm nylon mesh cell strainer (BD Biosciences, Oakville, ON, Canada). Isolated islets were hand-picked (purity >95%) and cultured in Ham’s-F10 (16.7 mmol/l glucose) for 7 days.
Dispersion of islets
Human or mouse islets (∼300) were dispersed in 150 μl dissociation buffer by gently pipetting up and down for 1 min followed by a 1 min rest repeated for a total of 5 min. Then 2 μl trypsin-EDTA (0.25%) and 1 μl DNase I (0.4 mg/ml) were added and dissociation continued for 1 min and stopped by adding 150 μl medium (CMRL: human islets; Ham’s-F10: mouse islets). Cells were centrifuged (500×g, 5 min, 4°C) and cell pellets were resuspended in 100 μl culture medium. Cell viability was assessed by Trypan Blue and cells were cultured in poly-l-lysine-coated plates in CMRL (human) or Ham’s-F10 (mouse) containing 5.5 and 10 mmol/l glucose, respectively.
Transformed cell lines
INS-1 (832/13) cells, a transformed rat beta cell line, and beta-TC3 and alpha-TC cells, mouse beta and alpha cell lines, respectively, were gifts from C. Newgard (Duke University Medical Center, NC, USA) and P. Halban (University of Geneva, Switzerland). Cells were grown in RPMI-1640 (INS-1) or DMEM (beta-TC3 and alpha-TC) containing 11.1 and 5.5 mmol/l glucose, respectively, supplemented with 10% (vol./vol.) FBS, 50 U/ml penicillin, 50 μg/ml streptomycin and 50 μmol/l 2-mercaptoethanol (INS-1).
Alamar Blue reduction assay
For assessment of cell viability, cells were incubated with Alamar Blue dye diluted 1:10 in medium for 3 h at 37°C. Fluorescence of control (blank) and samples were read (excitation: 530; emission: 590 nm) using a Fluoroskan Ascent plate reader (Thermo Labsystems, Helsinki, Finland) and data calculated as per cent of control.
Treatment with hIAPP, Congo Red or caspase inhibitors
Lyophilised hIAPP or rIAPP was dissolved in HFIP and incubated at room temperature for 1 h; aliquots were frozen (−80°C), lyophilised and kept (−20°C) until used. Stock hIAPP or rIAPP solutions were prepared freshly for each experiment by dissolving lyophilised aliquots in culture medium and added to INS-1 or dispersed islet cells, then cultured for different time points as detailed in figure legends. Stock Congo Red solution was prepared in DMSO, diluted in culture medium and added to cell cultures at a final concentration of 25 μmol/l before addition of hIAPP. Caspase-3 (z-DEVD-FMK) or pan-caspase (z-VD-FMK) inhibitors were added to cell cultures at a final concentration of 100 μmol/l 1 h before addition of hIAPP.
TUNEL, thioflavin S and immunolabelling
Paraffin-embedded islet or pancreatic sections were dewaxed, rehydrated and blocked in 2% (vol./vol.) normal goat or donkey serum (Vector Laboratories, Burlingame, CA, USA). For insulin (or glucagon) and TUNEL staining, fixed cells or histological sections (following antigen retrieval with citrate buffer) were incubated with guinea pig anti-insulin or rabbit anti-glucagon antibody (Dako, Carpinteria, CA, USA) at a 1:100 dilution at 4°C overnight, followed by incubation with Alexa Fluor 488-conjugated goat anti-guinea pig (or anti-rabbit) antibody (Molecular Probes, Eugene, OR, USA) for 1 h (1:100) at room temperature and TUNEL reaction mixture (Roche Diagnostics, Laval, QC, Canada) for 30 min (37°C). For insulin and active caspase-3 immunostaining, cells or islet/tissue sections (following antigen retrieval) were incubated with anti-insulin and Texas Red-conjugated goat anti-guinea pig antibody (Jackson Laboratory) for 1 h (1:100, room temperature), followed by incubation with anti-cleaved caspase-3 antibody (Cell Signaling, Pickering, ON, Canada) overnight (4°C, 1:50) and Alexa 488-conjugated anti-rabbit antibody (Molecular Probes) for 1 h (1:100, room temperature). For insulin and glucagon immunolabelling, following insulin staining, sections were similarly incubated with rabbit anti-glucagon (Dako) and Alexa 488-conjugated goat anti-rabbit antibodies and for thioflavin S staining incubated with 0.5% (wt/vol.) thioflavin S solution for 5 min. For quantification studies, sections were counterstained with the nuclear dye DAPI (Vector Laboratories).
Glucose-stimulated insulin secretion
Cultured mouse islets were pre-incubated (1 h) in Krebs–Ringer bicarbonate (KRB) buffer containing 10 mmol/l HEPES (pH 7.4), 0.25% (wt/vol.) BSA and 1.67 mmol/l glucose at 37°C followed by 1 h incubation in KRB containing 1.67 mmol/l glucose (basal insulin release) and then 1 h incubation in the same buffer containing 16.7 mmol/l glucose (stimulated insulin release). Islets were lysed in 100 μl lysis buffer containing 1 mol/l acetic acid/0.1% (wt/vol.) BSA followed by three times freeze-thawing. Incubation media and islet lysates were centrifuged and supernatant fractions were frozen (−20°C) until assayed. Insulin levels were measured using a mouse-specific insulin ELISA kit (ALPCO Diagnostics, Salem, NH, USA). Islet insulin content was reported as percentage of insulin content in cultured wild-type islets taken as 100% and the magnitude of insulin response to elevated glucose was calculated as fold increase over basal insulin release.
Data are expressed as means ± SEM. Statistical analyses were performed using one-way ANOVA followed by a Newman–Keuls test or by a Student’s t test, as appropriate. p < 0.05 was taken as significant. All experiments were performed in triplicate and repeated three to five times.
hIAPP-induced activation of caspase-3 and apoptosis are prevented by the amyloid-binding dye Congo Red
Exposure to hIAPP aggregates induces activation of caspase-3 and apoptosis in primary human and mouse islet beta cells
To further validate the role of caspase-3 in hIAPP-induced cytotoxicity in primary beta cells, freshly isolated mouse islets were dispersed into single cells and cultured with or without hIAPP. As expected, non-treated mouse islet cells had low numbers of active caspase-3- and TUNEL-positive beta cells. As with transformed beta cells, hIAPP treatment markedly increased the number of both active caspase-3- and TUNEL-positive islet beta cells, leading to lower beta cell/total islet cell ratio in hIAPP-treated islet cells compared with non-treated cells (Fig. 1e–g; ESM Fig. 1b). Similarly, exposure of cultured human islet cells to hIAPP markedly increased the proportion of active caspase-3- and TUNEL-positive beta cells, which was associated with a decrease in beta cell/total islet cell ratio (Fig. 1h–j; ESM Fig. 1b).
Islet beta cells are more susceptible than alpha cells to the cytotoxic effects of extracellular hIAPP aggregates
Inhibition of caspase-3 activation markedly reduces hIAPP-induced beta cell apoptosis
Deletion of caspase-3 in hIAPP-transgenic mouse islets prevents beta cell apoptosis induced by fibrillogenesis of endogenously expressed hIAPP and preserves beta cells during culture
The number of apoptotic alpha cells is comparable in cultured hIAPP-transgenic mouse islets expressing or lacking caspase-3
Double TUNEL and glucagon immunostaining revealed that despite the increased beta cell apoptosis induced by hIAPP aggregates formed by endogenously secreted hIAPP in cultured islets, the proportion of apoptotic alpha cells remained low (Fig. 4c, f). Furthermore, the proportion of apoptotic alpha cells was comparable in hIAPP-transgenic islets expressing and lacking caspase-3, leading to decreased islet beta/alpha cell ratio in hIAPP-transgenic mouse islets expressing caspase-3 compared with those lacking caspase-3 (Fig. 4g).
Reduced amyloid-induced beta cell death by deletion of caspase-3 in hIAPP-expressing mouse islets is associated with enhanced beta cell function during culture
We examined whether prevention of amyloid-induced caspase-3 activation and beta cell apoptosis enhances beta cell function in cultured hIAPP-expressing mouse islets. Following 7 day culture, islet insulin content and response to elevated glucose were reduced in hIAPP-expressing islets compared with wild-type islets (Fig. 4h, i). Insulin content and glucose response were increased by about 30% and 20%, respectively, in cultured islets expressing hIAPP but lacking caspase-3, compared with those expressing hIAPP and caspase-3. The absence of caspase-3 in islets expressing non-fibrillogenic mouse IAPP did not have any significant effect on insulin content or glucose response.
Amyloid formation in cultured human islets is associated with increased number of active caspase-3- and TUNEL-positive beta cells
Growing evidence suggests that hIAPP aggregates are toxic to beta cells and contribute to loss of beta cell mass in type 2 diabetes [3–5]. Furthermore, we have previously shown that amyloid formation in human  and hIAPP-expressing mouse islets  during culture is associated with beta cell death and that prevention of amyloid formation enhances survival and function of cultured islets [8, 16]. The recent report of amyloid formation in human islets that had been transplanted into a type 1 diabetic patient  supports the idea that amyloid formation may also play a role in beta cell dysfunction/death in islet grafts. Accordingly, amyloid formation in hIAPP-expressing mouse islet grafts [9, 42] has been shown to result in recurrence of hyperglycaemia in diabetic mouse recipients . Taken together, these findings suggest that amyloid formation may contribute to beta cell death through a similar mechanism in type 2 diabetes and in cultured and transplanted islets. The molecular mechanism(s) by which fibrillogenesis of endogenously produced hIAPP causes beta cell apoptosis are still not clear.
In this study we show, using two ex vivo models of islet amyloid formation, cultured human islets and hIAPP-expressing mouse islets lacking caspase-3, that caspase-3 has a key role in beta cell apoptosis induced by fibrillogenesis of endogenously produced hIAPP in islets and that deletion of caspase-3 protects islet beta cells from hIAPP aggregates formed during in situ islet culture. These findings provide direct evidence to support the hypothesis that aggregation of biosynthetic hIAPP produced by islet beta cells induces apoptosis, as least partially through activation of caspase-3. A key finding of our studies is that hIAPP, at concentrations found in islets in vivo such as type 2 diabetes and islet grafts, can induce activation of caspase-3.
Interestingly, our studies with both transformed and primary mouse islet cells revealed that alpha cells are markedly less susceptible to hIAPP toxicity than beta cells cultured under the same conditions. The finding that alpha cells survive much better than beta cells following exposure to hIAPP aggregates derived from both exogenously applied and endogenously produced hIAPP in cultured islets, suggests that the lower susceptibility of alpha cells to hIAPP toxicity cannot be explained solely by production of hIAPP by beta cells. Thus, other differences between alpha and beta cells appear to protect alpha cells from hIAPP aggregates in conditions associated with amyloid formation, such as culture, transplantation and type 2 diabetes. The particular susceptibility of beta cells to hIAPP may explain the selective beta cell death in type 2 diabetes.
Consistent with previous in vitro studies in transformed cell lines , we found that micromolar concentrations of synthetic hIAPP increases caspase-3 activation in INS-1 and primary islet beta cells. Furthermore, deletion of caspase-3 in mouse islet cells markedly decreased the proportion of apoptotic beta cells following hIAPP treatment. Taken together, these findings suggest that in both transformed and primary islet beta cells, exposure to aggregates derived from exogenously applied hIAPP induces caspase-3 activation and that inhibition of caspase-3 protects beta cells from exogenous hIAPP aggregates.
Amyloid fibrils are typically found extracellularly adjacent to beta cells in islets [10, 36, 43]. Intracellular amyloid-like aggregates have also been reported in human and hIAPP-overexpressing transgenic mouse islets transplanted into type 1 diabetic mice [4, 9, 44, 45]. Small hIAPP aggregates appear to be more toxic than large fibrils and are probably the major mediators of beta cell death [19–21, 46]. Despite convincing evidence implicating a membrane interaction in the cytotoxicity of exogenous synthetic hIAPP aggregates [19, 46, 47], the mode of this interaction is still unclear. Our studies show that prevention of hIAPP aggregation and interaction with beta cells by the amyloid-binding dye Congo Red, markedly reduces caspase-3 activation and apoptosis in INS-1 beta cells, supporting the notion that interaction of extracellular hIAPP aggregates with beta cell membranes induces caspase-3 activation and apoptosis. A recent study has demonstrated that exposure to synthetic hIAPP leads to upregulation of the cell membrane death receptor Fas in mouse islet beta cells in vitro , suggesting that hIAPP-induced beta cell apoptosis may involve activation of a Fas-mediated apoptotic pathway.
We generated a mouse model expressing hIAPP but lacking caspase-3 to directly investigate the potential role of caspase-3 in mediating the toxic effects of endogenously produced hIAPP aggregates in islets. Islets from hIAPP-expressing mice with or without caspase-3 expression had comparable levels of amyloid formation both in vitro and in vivo, confirming that the absence of caspase-3 per se does not have any detectable effect on amyloid formation in hIAPP-expressing mouse islets. As expected [16, 49], hIAPP aggregates were not detectable in freshly isolated hIAPP-expressing mouse islets but were present in cultured islets. Interestingly, hIAPP-expressing islets lacking caspase-3 had markedly lower apoptotic beta cells, higher insulin content and glucose response compared with islets expressing hIAPP and caspase-3, suggesting that deletion of caspase-3 protects islet beta cells from endogenously produced hIAPP aggregates and improves their survival and function. Importantly, despite significant increase in the proportion of active caspase-3 and apoptotic beta cells, the number of apoptotic alpha cells was low in cultured hIAPP-transgenic mouse islets expressing or lacking caspase-3.
To further validate these findings, we used cultured human islets as an independent model of islet amyloid formation. Consistent with our previous findings , thioflavin S-positive hIAPP aggregates were detectable in some but not all cultured human islets. Interestingly, most of the amyloid-positive islets had a higher number of active caspase-3 and apoptotic beta cells compared with amyloid-negative islets cultured under the same conditions, suggesting that hIAPP aggregates and not culture conditions per se contribute to caspase-3 activation and beta cell apoptosis. Despite amyloid formation, the number of apoptotic alpha cells was low in cultured human islets, leading to increased alpha/beta cell ratio. Less susceptibility of islet alpha cells to aggregates derived from biosynthetic hIAPP and selective amyloid-induced beta cell death may explain the increased islet alpha/beta cell ratio in conditions associated with islet amyloid formation. In support, amyloid formation associated with very low number of beta cells but high number of alpha cells was reported in the islet graft from a type 1 diabetic patient .
In summary, our studies show that inhibition of caspase-3 protects islet beta cells from the cytotoxic effects of endogenously secreted (and exogenously applied) hIAPP. Prevention of amyloid toxicity by short-term inhibition of caspase-3 may provide a new approach to increase survival/function of human islets during pre-transplant culture and possibly after transplantation. Finally, less susceptibility of alpha cells to hIAPP and selective amyloid-induced beta cell death may contribute to increased islet alpha/beta cell ratio in conditions associated with islet amyloid formation.
This work was supported by grants from the Canadian Institutes of Health Research to L. Marzban (MOP-81375) and M. Woo. Infrastructure support was provided by grants from the Canadian Foundation for Innovation (L. Marzban) and the Michael Smith Foundation for Health Research (MSFHR) to the Centre for Human Islet Transplantation and Beta-Cell Regeneration (G. L. Warnock). L. Marzban is a Scholar of the Canadian Diabetes Association and T. J. Kieffer is the recipient of a senior scholarship from the MSFHR. hIAPP-transgenic mice for these studies were kindly provided by S. Kahn (VA Puget Sound Health Care System, University of Washington, WA, USA). We gratefully acknowledge the outstanding technical assistance of M. Speck, I. Barta and A. Asadi in the completion of these studies.